ERBB2 and breast carcinoma: The purpose of this study is to perform PPK modeling in HER2-positive breast cancer patients to reflect the clinical use of pyrotinib and evaluate the impact factors, such as patient demographic information, pathophysiological and pharmacotherapeutic characteristics on the PK of pyrotinib in clinical application.